{"transactions":[{"id":729975,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-23T01:46:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":13562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":13562,"derivative":{"exercise_price":31.74,"exercise_date":"2027-06-18","expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":13562},"source":{"system":"sec-edgar","filing":"0001104659-26-076566","document":"tm2618519-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000110465926076566/tm2618519-1_4seq1.xml","form_type":"4"}},{"id":1091747,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:23:04.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061498","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390025061498/ownership.xml","form_type":"4"}},{"id":1104537,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-20T23:29:56.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":15502,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15502,"derivative":{"exercise_price":24.89,"exercise_date":"2026-06-18","expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":15502},"source":{"system":"sec-edgar","filing":"0001104659-25-061267","document":"tm2518583-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000110465925061267/tm2518583-1_4seq1.xml","form_type":"4"}},{"id":1280271,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:48:44.000Z","date":"2025-02-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-015339","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015339/ownership.xml","form_type":"4"}},{"id":1280270,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-06T15:48:44.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":28606,"price":3.65,"value":104411.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the \"Merger Agreement\"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation (\"Parent\"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub,\" and together with Parent, the \"Buyer Parties\"), pursuant to which Merger Sub completed a cash tender offer (the \"Offer\") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the \"Shares\"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the \"Per Share Price\"). These Issuer Shares were tendered for purchase pursuant to the Offer."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000950170-25-015339","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000095017025015339/ownership.xml","form_type":"4"}},{"id":1484380,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:28:49.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390024051414/ownership.xml","form_type":"4"}},{"id":1528119,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-03T08:46:21.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":23458,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":23458,"derivative":{"exercise_price":3.795,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":23458},"source":{"system":"sec-edgar","filing":"0001479290-24-000088","document":"wk-form4_1714740373.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000088/wk-form4_1714740373.xml","form_type":"4"}},{"id":1528118,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-03T08:46:21.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":43606,"source":{"system":"sec-edgar","filing":"0001479290-24-000088","document":"wk-form4_1714740373.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000088/wk-form4_1714740373.xml","form_type":"4"}},{"id":1667870,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-29T21:16:13.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":17884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":17884,"derivative":{"exercise_price":18,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":17884},"source":{"system":"sec-edgar","filing":"0001104659-24-007733","document":"tm244377-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000110465924007733/tm244377-2_4seq1.xml","form_type":"4"}},{"id":1861681,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:42:54.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390023047569/ownership.xml","form_type":"4"}},{"id":1902653,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-05-05T17:14:56.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":5915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":5915,"derivative":{"exercise_price":33.61,"expiration_date":"2033-05-02","underlying":"Common Stock","underlying_shares":5915},"source":{"system":"sec-edgar","filing":"0001479290-23-000062","document":"wf-form4_168332128227955.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000062/wf-form4_168332128227955.xml","form_type":"4"}},{"id":1902652,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-05T17:14:56.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":3534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Nolet's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":28606,"source":{"system":"sec-edgar","filing":"0001479290-23-000062","document":"wf-form4_168332128227955.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929023000062/wf-form4_168332128227955.xml","form_type":"4"}},{"id":2054026,"issuer":{"id":117561,"kind":"organization","name":"POLARITYTE, INC.","symbol":"PTE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-01-17T16:30:29.000Z","date":"2023-01-12","kind":"exercise","acquired":false,"shares":3078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable."}],"balance_after":6157,"derivative":{"exercise_price":22.5,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":9235},"source":{"system":"sec-edgar","filing":"0001493152-23-001628","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076682/000149315223001628/ownership.xml","form_type":"4"}},{"id":2054025,"issuer":{"id":117561,"kind":"organization","name":"POLARITYTE, INC.","symbol":"PTE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T16:30:29.000Z","date":"2023-01-12","kind":"exercise","acquired":false,"shares":36497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited."}],"balance_after":14403,"source":{"system":"sec-edgar","filing":"0001493152-23-001628","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076682/000149315223001628/ownership.xml","form_type":"4"}},{"id":2137462,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-10-14T00:00:58.000Z","date":"2022-10-12","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001213900-22-063938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390022063938/ownership.xml","form_type":"4"}},{"id":2145633,"issuer":{"id":117561,"kind":"organization","name":"POLARITYTE, INC.","symbol":"PTE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T17:00:55.000Z","date":"2022-10-01","kind":"grant","acquired":true,"shares":50900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears."}],"balance_after":50900,"source":{"system":"sec-edgar","filing":"0001493152-22-027578","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076682/000149315222027578/ownership.xml","form_type":"4"}},{"id":2271982,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-13T18:11:40.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":10756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy."}],"balance_after":10756,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":10756},"source":{"system":"sec-edgar","filing":"0001479290-22-000067","document":"wf-form4a_165247985603673.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000067/wf-form4a_165247985603673.xml","form_type":"4/A","original_submission_date":"2022-05-06"}},{"id":2279282,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-05-06T18:19:36.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":11343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":11343,"derivative":{"exercise_price":18.12,"expiration_date":"2032-05-03","underlying":"Common Stock","underlying_shares":11343},"source":{"system":"sec-edgar","filing":"0001479290-22-000063","document":"wf-form4_165187555569277.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000063/wf-form4_165187555569277.xml","form_type":"4"}},{"id":2279281,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-06T18:19:36.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":6059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":25072,"source":{"system":"sec-edgar","filing":"0001479290-22-000063","document":"wf-form4_165187555569277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929022000063/wf-form4_165187555569277.xml","form_type":"4"}},{"id":2319666,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T22:01:54.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":78045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option shall vest on December 7, 2022, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":78045,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":78045},"source":{"system":"sec-edgar","filing":"0001213900-22-014564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782814/000121390022014564/ownership.xml","form_type":"4"}},{"id":2723090,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-05-07T19:10:38.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":7551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":7551,"derivative":{"exercise_price":27.91,"expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":7551},"source":{"system":"sec-edgar","filing":"0001479290-21-000112","document":"wf-form4_162042902149962.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000112/wf-form4_162042902149962.xml","form_type":"4"}},{"id":2723089,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-07T19:10:38.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":4013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":19013,"source":{"system":"sec-edgar","filing":"0001479290-21-000112","document":"wf-form4_162042902149962.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929021000112/wf-form4_162042902149962.xml","form_type":"4"}},{"id":2788626,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:15:21.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":7358,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the \"Merger Agreement\"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. (\"Purchaser\"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."}],"balance_after":0,"derivative":{"exercise_price":48.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":7358},"source":{"system":"sec-edgar","filing":"0000899243-21-011497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011497/doc4.xml","form_type":"4"}},{"id":2788625,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-15T09:15:21.000Z","date":"2021-03-15","kind":"disposition_to_issuer","acquired":false,"shares":26210,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the \"Merger Agreement\"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. (\"Purchaser\"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":26210},"source":{"system":"sec-edgar","filing":"0000899243-21-011497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924321011497/doc4.xml","form_type":"4"}},{"id":2922263,"issuer":{"id":117561,"kind":"organization","name":"POLARITYTE, INC.","symbol":"PTE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (Right to Buy)","published_at":"2021-01-05T16:10:35.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":166443,"price":0.48,"value":79892.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 1, 2021, the reporting person was issued a common stock option under the issuer's 2017 Equity Incentive Plan for 166,443 shares vesting in 12 monthly installments beginning February 1, 2021 with a fair value of $0.48 per option share as annual compensation awarded under the issuer's non-executive director compensation plan."}],"balance_after":166443,"derivative":{"exercise_price":0.68,"exercise_date":"2021-02-01","expiration_date":"2031-01-01","underlying":"Common Stock","underlying_shares":166443},"source":{"system":"sec-edgar","filing":"0001493152-21-000207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076682/000149315221000207/ownership.xml","form_type":"4"}},{"id":3101456,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-23T16:44:21.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":7358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on the first anniversary date of the grant."}],"balance_after":7358,"derivative":{"exercise_price":48.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":7358},"source":{"system":"sec-edgar","filing":"0001209191-20-038491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000120919120038491/doc4.xml","form_type":"4"}},{"id":3147223,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-05-15T18:41:30.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest May 14, 2021, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":19.4,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001479290-20-000068","document":"wf-form4_158958247346516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000068/wf-form4_158958247346516.xml","form_type":"4"}},{"id":3147222,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T18:41:30.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual restricted stock award (the \"RSA\") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the \"Compensation Policy\").  The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001479290-20-000068","document":"wf-form4_158958247346516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929020000068/wf-form4_158958247346516.xml","form_type":"4"}},{"id":3180948,"issuer":{"id":117561,"kind":"organization","name":"POLARITYTE, INC.","symbol":"PTE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-07T16:30:13.000Z","date":"2020-04-06","kind":"grant","acquired":true,"shares":230894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a three-year period with one third vesting on each anniversary of the grant date."}],"balance_after":230894,"derivative":{"exercise_price":0.9,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":230894},"source":{"system":"sec-edgar","filing":"0001493152-20-005993","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076682/000149315220005993/ownership.xml","form_type":"4"}},{"id":3400307,"issuer":{"id":141253,"kind":"organization","name":"Viela Bio, Inc.","symbol":"VIE"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-02T21:51:12.000Z","date":"2019-10-02","kind":"grant","acquired":true,"shares":26210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a three-year period with one third vesting on each anniversary of the grant date."}],"balance_after":26210,"derivative":{"exercise_price":19,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":26210},"source":{"system":"sec-edgar","filing":"0000899243-19-024843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1734517/000089924319024843/doc4.xml","form_type":"4"}},{"id":3459192,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-07-18T20:29:21.000Z","date":"2019-07-16","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest on July 16, 2020, the one year anniversary of the grant date, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date."}],"balance_after":18000,"derivative":{"exercise_price":12.32,"expiration_date":"2029-07-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001479290-19-000083","document":"wf-form4_156349614702794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000083/wf-form4_156349614702794.xml","form_type":"4"}},{"id":3459191,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36205,"kind":"person","name":"Nolet Chris","position":1,"cik":"0001782814","reported_name":"Nolet Chris","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-18T20:29:21.000Z","date":"2019-07-16","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an initial restricted stock award (the \"RSA\"). The shares underlying the RSA shall vest on July 16, 2020, the one year anniversary from the grant date, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) through such vesting date."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0001479290-19-000083","document":"wf-form4_156349614702794.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929019000083/wf-form4_156349614702794.xml","form_type":"4"}}]}